AZOTH

Azoth Bio is an artificial intelligence-driven biotechnology company focused on the discovery and development of novel small molecule therapeutics for challenging diseases. The company utilizes a proprietary AI platform that integrates deep learning with structural biology and high-performance computing to predict drug-target interactions and optimize lead compounds with high precision. Founded by experts from MD Anderson Cancer Center, Azoth Bio primarily targets high-value, traditionally 'undruggable' proteins in the field of oncology. By streamlining the hit-to-lead process, the company aims to significantly reduce the time and cost associated with traditional drug discovery. Azoth Bio operates at the intersection of computational data science and medicinal chemistry to advance its internal pipeline of next-generation cancer therapies.